• About Us
    • Board of Directors
    • Advisors
    • Committees
    • Staff
  • Our Work
    • In The News
    • Newsletter Archive
  • Programs
    • Scholarship Program
  • Join Now
    • Veterinary Professional
    • Pet Parents
    • Product Industry
    • Login
  • Directory of Practitioners
  • Get Involved
    • Make A Donation
    • Become A Corporate Sponsor
    • Join Email List
  • Contact
  • DONATE
  • Members Dashboard
Veterinary Cannabis SocietyVeterinary Cannabis Society
  • About Us
    • Board of Directors
    • Advisors
    • Committees
    • Staff
  • Our Work
    • In The News
    • Newsletter Archive
  • Programs
    • Scholarship Program
  • Join Now
    • Veterinary Professional
    • Pet Parents
    • Product Industry
    • Login
  • Directory of Practitioners
  • Get Involved
    • Make A Donation
    • Become A Corporate Sponsor
    • Join Email List
  • Contact
  • DONATE
  • Members Dashboard

Pharmacokinetic Evaluation of a Cannabidiol Supplement in Horses

Home Pharmacokinetic Evaluation of a Cannabidiol Supplement in Horses

Curated Research Library

  • Back to Curated Research Library

Pharmacokinetic Evaluation of a Cannabidiol Supplement in Horses

  • By: Williams, M. R., Holbrook, T. C., Maxwell, L., Croft, C. H., Ientile, M. M., & Cliburn, K.
  • Published On: 2 March, 2022
  • Publication: sciencedirect.com
  • Tags: Equine
  • Category: Large Animal

Cannabidiol (CBD) products have gained popularity among horse owners despite limited evidence regarding pharmacokinetics. The purpose of this study was to describe the pharmacokinetic profile of multiple doses of an orally administered cannabidiol product formulated specifically for horses. A randomized 2-way crossover design was used. Seven horses received 0.35 or 2.0 mg/kg CBD per os every 24 hours for 7 total doses, separated by a 2-week washout. Plasma CBD and delta-9-tetrahydrocannabinol (THC) were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) daily through day 10, then on day 14 after beginning CBD administration. On the final day of CBD administration, plasma CBD and THC were quantified at multiple times. After administration of 0.35 mg/kg of CBD, the Cmax of CBD was 6.6 ± 2.1 ng/mL while Tmax was 1.8 ± 1.2 hour, whereas the Cmax for THC was 0.7 ± 0.6 ng/mL with a Tmax of 2.5 ± 1 hour. After administration of 2.0 mg/kg of CBD, the Cmax of CBD was 51 ± 14 ng/mL with a mean Tmax of 2.4 ± 1.1 hour and terminal phase half-life of 10.4 ± 6 hour, whereas the Cmax of THC was 7.5 ± 2.2 ng/mL with a Tmax of 2.9 ± 1.1 hour. Oral administration of a cannabidiol product at 0.35 mg/kg or 2.0 mg/kg once daily for 7 days was well-tolerated. Based on plasma CBD levels obtained, dose escalation trials in the horse evaluating clinical efficacy at higher mg/kg dose rates are indicated.

Click Here to Access Article
  • Back to Curated Research Library
Search

Our Mission is to create lasting solutions that ensure the safe use of cannabis in pets through education, advocacy, and promoting product standards.

Our Vision is an educated and empowered global veterinary medical cannabis community.

  • About Us
  • Our Work
  • Members Area
  • Get Involved
  • Contact Us
  • Donate

Email:
Click here to email us

Florida Mailing Address
7901 4th St. North, Suite 4404
St. Petersburg, FL 33702

California Mailing Address
4382 Piedmont Avenue
Oakland, CA 94611

Veterinary Cannabis Society is a nonprofit, 501(c)(3) organization in the United States. Tax ID #85-0986090

Veterinary Cannabis Society does not endorse any specific products.

© 2023 · Veterinary Cannabis Society

  • Terms of Use
  • Privacy Policy
  • State Notices
  • Contact